Molbio Diagnostics Ltd (MOLBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Molbio Diagnostics Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026.
Intimation · 05 Nov 2026, 5:30 pm
Molbio Diagnostics Schedules Q2 and H1 FY27 Earnings Conference Call Molbio Diagnostics Limited will host its Q2 and H1 FY27 earnings conference call on 5th Nov'26 at 05:30 PM IST to discuss financial performance for the period ended 30th Sep'26. Key management participants include CEO Sriram Natarajan, CTO Dr. Chandrasekhar Nair, CFO Manan Bimal Khokhani, and senior leadership from business development and corporate strategy.
To consider and approve the Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
MOLBIO DIAGNOSTICS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Molbio Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited financial ....
Intimation · 05 Nov 2026, 5:30 am
Molbio Diagnostics Schedules Board Meeting for Q2 FY27 Financial Results Molbio Diagnostics Limited has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed from 1st Oct'26 until 48 hours after the declaration of the financial results.
Clarification on Spurt in Volume of shares of the Company.
Others (Uncategorized) · 19 Oct 2026, 7:53 pm
Molbio Diagnostics Clarifies Share Trading Volume Surge Is Purely Market-Driven Molbio Diagnostics responded to BSE's query on 19th Oct'26 regarding a significant surge in trading volumes across stock exchanges. The company clarified that the volume movement is purely market-driven, confirming full compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. Management affirmed that no undisclosed events, price-sensitive information, or announcements remain pending for regulatory submission.
The Exchange has sought clarification from Molbio Diagnostics Ltd on October 19, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Others (Uncategorized) · 19 Oct 2026, 7:51 pm
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund
Acquisition/ Disposal of Shares · 16 Oct 2026, 3:43 pm
Kotak Mahindra Mutual Fund Acquires Over 5% Stake in Molbio Diagnostics Kotak Mahindra Mutual Fund (KMMF) crossed the 5% regulatory threshold in Molbio Diagnostics Ltd on 8th Oct'26 through an open market transaction. KMMF acquired 570,000 equity shares, representing a 0.4946% stake in the company. Following this acquisition, KMMF’s total holding increased from 5,749,083 shares (4.9888%) to 6,319,083 equity shares, raising its aggregate shareholding and voting rights to 5.4834% of Molbio Diagnostics' total paid-up equity share capital.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kotak Mahindra Mutual Fund
Acquisition/ Disposal of Shares · 13 Oct 2026, 3:52 pm
Kotak Mahindra Mutual Fund Increases Stake in Molbio Diagnostics Beyond 5% Kotak Mahindra Mutual Fund acquired 570,000 equity shares (a 0.4946% stake) of Molbio Diagnostics Limited via open market purchases on 8th Oct'26. Following this transaction, the fund's aggregate holding increased from 5,749,083 shares (4.9888%) to 6,319,083 shares, representing 5.4834% of the company's total equity share and voting capital. Molbio Diagnostics' total paid-up equity base stands unchanged at 11,52,39,996 shares of ₹1 face value each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
Acquisition/ Disposal of Shares · 01 Oct 2026, 9:10 pm
India Business Excellence Fund III Trims Stake in Molbio Diagnostics to 8.92% India Business Excellence Fund III, managed by MO Alternate Investment Advisors, offloaded 30,00,000 equity shares (2.60% stake) of Molbio Diagnostics Limited via open market sale on 23rd Sep'26. Following this disposal, the fund's equity holding in Molbio Diagnostics decreased from 11,52,39,996 shares (11.52%) to 11,22,39,996 shares (8.92%). The regulatory disclosure was triggered after breaching the 2% statutory threshold under SEBI SAST Regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III,
Acquisition/ Disposal of Shares · 01 Oct 2026, 3:50 pm
India Business Excellence Fund III Trims Stake in Molbio Diagnostics India Business Excellence Fund III, managed by MO Alternate Investment Advisors, sold 23,77,627 equity shares (2.06% stake) of Molbio Diagnostics Ltd via the open market on 30th Sep'26. Following this disposal, the fund's shareholding in the company decreased from 1,02,76,750 equity shares (8.92% of total voting capital) to 78,99,123 equity shares (6.85%). The transaction breached the 2% threshold under Regulation 29(2) of SEBI SAST Regulations, triggering the statutory disclosure. Total voting capital post-transaction remains unchanged at 11,52,39,996 equity shares.
Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 25, 2026 for re-appointment of M/s K. S. Kamalakara & Co, Cost Accountants as the Cost Auditor of the Company for FY 2026-27.
Outcome · 25 Sept 2026, 6:59 pm
Molbio Diagnostics Reappoints K.S. Kamalakara & Co as Cost Auditor for FY27 Molbio Diagnostics Limited's Board of Directors approved the reappointment of Bengaluru-based M/s K. S. Kamalakara & Co, Cost Accountants (FRN: 000296), as the company's Cost Auditors during its meeting on 25th Sep'26. The peer-reviewed firm, led by founding partner CMA K. S. Kamalakara, will conduct the audit of the company's cost accounts for FY27.
Intimation of re-appointment of Cost Auditor of the Company pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 25 Sept 2026, 6:51 pm
Molbio Diagnostics Reappoints K.S. Kamalakara & Co. as Cost Auditor Molbio Diagnostics Limited's Board of Directors approved the reappointment of M/s K. S. Kamalakara & Co, Cost Accountants (FRN: 000296), as the company's Cost Auditors on 25th Sep'26. The peer-reviewed, Bengaluru-based firm will conduct the audit of cost accounts for FY27 (Financial Year 2026-27).
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
Acquisition/ Disposal of Shares · 25 Sept 2026, 6:44 pm
India Business Excellence Fund III Trims Stake in Molbio Diagnostics to 8.92% India Business Excellence Fund III sold 30,00,000 equity shares (2.60% stake) of Molbio Diagnostics Limited via the open market on 23rd Sep'26. Following the transaction, the fund's shareholding decreased from 1,32,76,750 shares (11.52%) to 1,02,76,750 shares (8.92% of total voting capital). The disposal triggered SEBI SAST Regulation 29(2) reporting requirements by breaching the 2% threshold limit. Total paid-up equity share capital of Molbio Diagnostics remains unchanged at 11,52,39,996 shares of INR 1 face value each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
Acquisition/ Disposal of Shares · 25 Sept 2026, 5:13 pm
India Business Excellence Fund III Trims Stake in Molbio Diagnostics India Business Excellence Fund III, managed by MO Alternate Investment Advisors, sold 30,00,000 equity shares (2.60% stake) of Molbio Diagnostics Limited via the open market on 23rd Sep'26. Following this disposal, the fund's equity holding in Molbio Diagnostics decreased from 11,52,39,996 shares (11.52% of total voting capital) to 11,22,39,996 shares (8.92% of total voting capital). The transaction triggered regulatory disclosure requirements after breaching the 2% statutory threshold under SEBI Takeover Regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
Acquisition/ Disposal of Shares · 24 Sept 2026, 8:35 pm
India Business Excellence Fund III Trims Stake in Molbio Diagnostics India Business Excellence Fund III offloaded 30,00,000 equity shares (a 2.60% stake) of Molbio Diagnostics Ltd. via open market sale on 23rd Sep'26. Consequently, the fund's equity holding decreased from 11,52,39,996 shares (11.52%) to 11,22,39,996 shares (8.92%). The disclosure under Regulation 29(2) of SEBI SAST Regulations was triggered after breaching the statutory 2% change threshold. Total diluted voting capital post-transaction stands at 8.92%.
Intimation of Analysts/Investors Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, scheduled to be held on Tuesday, September ....
Intimation · 17 Sept 2026, 8:53 pm
Molbio Diagnostics Schedules Virtual Analyst and Investor Meeting for September 2026 Molbio Diagnostics Limited has scheduled an interaction with investors and analysts via a virtual group meeting on 22nd Sep'26 at 11:00 AM IST onwards. According to the regulatory filing under SEBI LODR Regulation 30, discussions will focus strictly on the general business outlook and publicly available information, with no unpublished price-sensitive information to be shared.
Pursuant to Regulation 30 of the SEBI(LODR),2015, Please find attached herewith the Transcripts of the Earning call held on September 08,2026 in relation to the Fianncial Results for the ....
Transcript · 12 Sept 2026, 3:44 pm
Intimation of Change of Corporate Identification Number (CIN) of the company.
Others (Uncategorized) · 09 Sept 2026, 5:47 pm
Molbio Diagnostics Updates Corporate Identification Number Following Stock Exchange Listing Following the listing of its equity shares on the NSE and BSE on 17th Aug'26, Molbio Diagnostics Limited announced that the Registrar of Companies, Goa, has updated its Corporate Identification Number (CIN) from U33125GA2000PLC002909 to L33125GA2000PLC002909. In line with the listing status, the company’s classification on the Ministry of Corporate Affairs (MCA) portal has formally transitioned from "Unlisted" to "Listed."
Audio Recording of Earnings Call for the quarter ended June 30, 2026.
Audio / Video · 08 Sept 2026, 11:47 pm
Molbio Diagnostics Releases Earnings Call Audio Recording for Quarter Ended June 2026 Molbio Diagnostics Limited informed stock exchanges that the audio recording of its earnings conference call held on 8th Sep'26 has been made available on its official website. The earnings call discussed the standalone and consolidated financial results of the company for the quarter ended 30th Jun'26, in compliance with Regulations 30 and 46 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.
Investor Presentation · 08 Sept 2026, 8:27 pm
Molbio Diagnostics Q1 FY27 Performance Update Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 Cr, up from ₹100.5 Cr in Q1 FY26, boosted by ~₹57 Cr of deferred Q4 FY26 export orders. EBITDA turned around to ₹103.7 Cr (25.2% margin) versus a loss of ₹14.5 Cr in Q1 FY26, while PAT reached ₹52.7 Cr against a net loss of ₹23.9 Cr. Growth was driven by Truenat test kit volumes reaching 6.2 Mn units. Capacity utilization stood at 58.25% for test kits and 42.30% for devices in FY26.
Molbio Diagnostics Limited has informed the Exchange regarding the Press Release for the Quarter ended June 30,2026.
Press Release · 07 Sept 2026, 3:22 pm
Molbio Diagnostics Q1 FY27 Results: Strong Turnaround Driven by Truenat Kit Volumes Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr, up sharply from ₹100.47 Cr in Q1 FY26, boosted by Truenat test kit volumes reaching 6.24 Mn units and ~₹57 Cr in deferred Q4 FY26 export orders. The company turned profitable YoY, posting an EBITDA of ₹103.68 Cr (25.20% margin) versus a ₹14.50 Cr loss, and PAT of ₹52.74 Cr (12.82% margin) versus a ₹23.94 Cr loss. Following its 17th Aug'26 listing, IPO proceeds are funding automation and a Bengaluru R&D facility.
The Board of Directors at their meeting held on Saturday, September 05, 2026 approved the Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30, 2026
Outcome · 06 Sept 2026, 2:24 am
Outcome of the Board Meeting held on Saturday, September 05,2026.
Financial Result · 06 Sept 2026, 12:29 am
Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 06 Sept 2026, 12:23 am
Intimation of Earnings Conference Call under Regulation 30 and all other applicable regulations, if any, of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) ....
Intimation · 08 Sept 2026, 4:00 pm
Molbio Diagnostics Schedules Q1 FY27 Earnings Conference Call Molbio Diagnostics (BSE: 544866, NSE: MOLBIO) will host its Q1 FY27 earnings conference call on 8th Sep'26 at 04:00 PM IST to discuss financial results for the quarter ended 30th Jun'26. The session will be conducted via Zoom. Key management participants addressing investors include CEO Sriram Natarajan, CTO Dr. Chandrasekhar Nair, and CFO Manan Bimal Khokhani. Attendees are advised to log in five minutes prior to the scheduled start.